Garafola, Svetlana
Shiferaw, Elizabeth
Dev, Vikram
Funding for this research was provided by:
Sage Therapeutics
Article History
Accepted: 25 April 2023
First Online: 6 June 2023
Declarations
:
: This surveillance program was funded by Sage Therapeutics, Inc.
: SG and ES are employees of Sage Therapeutics, Inc., and may hold stock and/or stock options. VD was an employee of Sage Therapeutics, Inc., at the time of this report, and may hold stock and/or stock options.
: Not applicable.
: All patients reviewed the ZULRESSO<sup>®</sup> Patient Information Guide and enrolled in the REMS program by completing the Patient Enrollment Form with a healthcare provider.
: Not applicable.
: The data that support the findings of this postmarketing surveillance program are available from the corresponding author upon reasonable request.
: Not applicable.
: All authors contributed to data interpretation and writing of the manuscript. All authors approved the final draft for submission.